

Dow



GB00 | 3562



PCT/GB 00/03562



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

4

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that by virtue of an assignment registered under the Patents Act 1977, the application is now proceeding in the name as substituted.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Anastasias

Dated 20 September 2000

THIS PAGE BLANK (USPTO)

GB9922173.1

By virtue of a direction given under Section of the Patents Act 1977, the application is proceeding in the name of

ASTRAZENECA AB,
Incorporated in Sweden,
S-151 85 Sodertalje,
Sweden

[ADP No. 07822448003]

THIS PAGE BLANK (USPTO)

GB9922173.1


By virtue of a direction given under Section of the Patents Act 1977, the application is proceeding in the name of

ASTRAZENECA UK LIMITED
Incorporated in the United Kingdom
15 Stanhope Gate
LONDON
W1Y 6QH
United Kingdom

[ADP No. 07810294001]

SECTION 19(1) ACT 1977
APPLICATION FILED 4/12/09

THIS PAGE BLANK (USPTO)



21 SEP 1999

The Patent
Offic21SEP99 E477988-3 D02934
P01/7700 0.00 - 9922173.1**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

PHM 99-142

2. Patent application number

(The Patent Office will fill in this part)

9922173.1

21 SEP 1999

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)Zeneca Limited
15 Stanhope Gate
LONDON
W1Y 6LN, GBPatents ADP number (*if you know it*)

SECTION 30 (1977 ACT) APPLICATION FILED 9/3/00

6254007002

4. Title of the invention

CHEMICAL COMPOUNDS

5. Name of your agent (*if you have one*)

BILL, Kevin

"Address for service" in the United Kingdom to which all correspondence should be sent
(*including the postcode*)

AstraZeneca PLC
Global Intellectual Property
Mereside, Alderley Park,
Macclesfield, Cheshire, SK10 4TG, GB

Patents ADP number (*if you know it*)

44698470023

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country	Priority application number (<i>if you know it</i>)	Date of filing (<i>day / month / year</i>)
---------	--	---

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (<i>day / month / year</i>)
-------------------------------	---

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- no answer (n/a)

Patents Form 1/77

Knowing recent publications may affect your application
Do not count copies of the same document

Continuation sheets of this form

Description

Claim(s)

Abstract

Drawing(s)

47

10. If you are also filing any of the following,
state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right
to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination
and search (*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Lynda May Slack

Date

22 September 1999

12. Name and daytime telephone number of
person to contact in the United Kingdom

Mrs Lynda May Slack 01625 516173

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.

CHEMICAL COMPOUNDS

The present invention relates to certain quinazoline derivatives for use in the treatment of certain diseases in particular to proliferative disease such as cancer and in the preparation of medicaments for use in the treatment of proliferative disease, to novel quinazoline compounds and to processes for their preparation, as well as pharmaceutical compositions containing them as active ingredient.

Cancer (and other hyperproliferative disease) is characterised by uncontrolled cellular proliferation. This loss of the normal regulation of cell proliferation often appears to occur as the result of genetic damage to cellular pathways that control progress through the cell cycle.

In eukaryotes, the cell cycle is largely controlled by an ordered cascade of protein phosphorylation. Several families of protein kinases that play critical roles in this cascade have now been identified. The activity of many of these kinases is increased in human tumours when compared to normal tissue. This can occur by either increased levels of expression of the protein (as a result of gene amplification for example), or by changes in expression of co activators or inhibitory proteins.

The first identified, and most widely studied of these cell cycle regulators have been the cyclin dependent kinases (or CDKs). Activity of specific CDKs at specific times is essential for both initiation and coordinated progress through the cell cycle. For example, the CDK4 protein appears to control entry into the cell cycle (the G0-G1-S transition) by phosphorylating the retinoblastoma gene product pRb. This stimulates the release of the transcription factor E2F from pRb, which then acts to increase the transcription of genes necessary for entry into S phase. The catalytic activity of CDK4 is stimulated by binding to a partner protein, Cyclin D. One of the first demonstrations of a direct link between cancer and the cell cycle was made with the observation that the Cyclin D1 gene was amplified and cyclin D protein levels increased (and hence the activity of CDK4 increased) in many human tumours (Reviewed in Sherr, 1996, Science 274: 1672-1677; Pines, 1995, Seminars in Cancer Biology 6: 63-72). Other studies (Loda et al., 1997, Nature Medicine 3(2): 231-234; Gemma et al., 1996, International Journal of Cancer 68(5): 605-11; Elledge et al. 1996, Trends in Cell Biology 6: 388-392) have shown that negative regulators of CDK function are frequently

down regulated or deleted in human tumours again leading to inappropriate activation of these kinases.

More recently, protein kinases that are structurally distinct from the CDK family have been identified which play critical roles in regulating the cell cycle and which also appear to 5 be important in oncogenesis. These include the newly identified human homologues of the


Drosophila aurora and *S.cerevisiae Ipl1* proteins. *Drosophila aurora* and *S.cerevisiae Ipl1*, which are highly homologous at the amino acid sequence level, encode serine/threonine protein kinases. Both aurora and Ipl1 are known to be involved in controlling the transition from the G2 phase of the cell cycle through mitosis, centrosome function, formation of a 10 mitotic spindle and proper chromosome separation / segregation into daughter cells. The two human homologues of these genes, termed aurora1 and aurora2, encode cell cycle regulated protein kinases. These show a peak of expression and kinase activity at the G2/M boundary (aurora2) and in mitosis itself (aurora1). Several observations implicate the involvement of human aurora proteins , and particularly aurora2 in cancer. The aurora2 gene maps to 15 chromosome 20q13, a region that is frequently amplified in human tumours including both breast and colon tumours. Aurora2 may be the major target gene of this amplicon, since aurora2 DNA is amplified and aurora2 mRNA overexpressed in greater than 50% of primary human colorectal cancers. In these tumours aurora2 protein levels appear greatly elevated compared to adjacent normal tissue. In addition, transfection of rodent fibroblasts with human 20 aurora2 leads to transformation, conferring the ability to grow in soft agar and form tumours in nude mice (Bischoff et al., 1998, The EMBO Journal. 17(11): 3052-3065). Other work (Zhou et al., 1998, Nature Genetics. 20(2): 189-93) has shown that artificial overexpression of aurora2 leads to an increase in centrosome number and an increase in aneuploidy.

Importantly, it has also been demonstrated that abrogation of aurora2 expression and 25 function by antisense oligonucleotide treatment of human tumour cell lines (WO 97/22702 and WO 99/37788) leads to cell cycle arrest in the G2 phase of the cell cycle and exerts an antiproliferative effect in these tumour cell lines. This indicates that inhibition of the function of aurora2 will have an antiproliferative effect that may be useful in the treatment of human tumours and other hyperproliferative diseases.

A number of quinazoline derivatives have been proposed hitherto for use in the inhibition of various kinases. Examples of such proposals are included in uS Patent No 5646153.

The applicants have found a series of compounds which inhibit the effect of the aurora2 kinase and which are thus of use in the treatment of proliferative disease such as cancer, in particular in such diseases such as colorectal or breast cancer where aurora 2 kinase is known to be active.

The present invention provides a compound of formula (I)



10

(I)

or a salt, ester or amide thereof;

where X is O, or S, S(O) or S(O)₂, NH or NR¹⁰ where R¹⁰ is hydrogen or C₁₋₆alkyl;;

15 R⁵ is a group OR¹¹, NR¹²R¹³ or SR¹¹ where R¹¹, R¹² and R¹³ are independently selected from optionally substituted hydrocarbyl or optionally substituted heterocyclic groups, and R¹² and R¹³ may additionally form together with the nitrogen atom to which they are attached, an aromatic or non-aromatic heterocyclic ring which may contain further heteroatoms,

R⁸ and R⁹ are independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋

20 alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₅alkenyl, C₂₋₅alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or unsaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group

may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂₋₄alkanoyl, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl,
 5 aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C₁₋₁₀alkoxycarbonyl, and

R¹, R², R³, R⁴ are independently selected from, halo, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, -NR¹⁴R¹⁵ (wherein R¹⁴ and R¹⁵, which may be the same or different, each represents hydrogen or C₁₋₃alkyl), or -X¹R¹⁶ (wherein X¹ represents a direct bond, -O-, -CH₂-, -OCO-, carbonyl, -S-, -SO-, -SO₂-, -NR¹⁷CO-, -CONR¹⁸-, -SO₂NR¹⁹-, -NR²⁰SO₂- or -NR²¹- (wherein R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and R¹⁶ is selected from one of the following eighteen groups:

1) hydrogen or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro or amino,

2) C₁₋₅alkylX²COR²² (wherein X² represents -O- or -NR²³- (in which R²³ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²² represents C₁₋₃alkyl, -NR²⁴R²⁵ or -OR²⁶ (wherein R²⁴, R²⁵ and R²⁶ which may be the same or different each represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl));

3) C₁₋₅alkylX³R²⁷ (wherein X³ represents -O-, -S-, -SO-, -SO₂-, -OCO-, -NR²⁸CO-, -CONR²⁹-, -SO₂NR³⁰-, -NR³¹SO₂- or -NR³²- (wherein R²⁸, R²⁹, R³⁰, R³¹ and R³² each independently

25 represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁷ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl and
 30 C₁₋₄alkoxy);

- 4) $C_{1-5}alkylX^4C_{1-5}alkylX^5R^{35}$ (wherein X^4 and X^5 which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR³⁶CO-, -CONR³⁷-, -SO₂NR³⁸-, -NR³⁹SO₂- or -NR⁴⁰- (wherein R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁵ represents hydrogen or C₁₋₃alkyl);
- 5) R^{41} (wherein R⁴¹ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl and C₁₋₄alkylsulphonylC₁₋₄alkyl);
- 6) $C_{1-5}alkylR^{41}$ (wherein R⁴¹ is as defined hereinbefore);
- 7) $C_{2-5}alkenylR^{41}$ (wherein R⁴¹ is as defined hereinbefore);
- 8) $C_{2-5}alkynylR^{41}$ (wherein R⁴¹ is as defined hereinbefore);
- 9) R^{42} (wherein R⁴² represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -CONR⁴³R⁴⁴ and -NR⁴⁵COR⁴⁶ (wherein R⁴³, R⁴⁴, R⁴⁵ and R⁴⁶, which may be the same or different, each represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl));
- 10) $C_{1-5}alkylR^{42}$ (wherein R⁴² is as defined hereinbefore);
- 11) $C_{2-5}alkenylR^{42}$ (wherein R⁴² is as defined hereinbefore);
- 12) $C_{2-5}alkynylR^{42}$ (wherein R⁴² is as defined hereinbefore);
- 13) $C_{1-5}alkylX^6R^{42}$ (wherein X⁶ represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁷CO-, -CONR⁴⁸-, -SO₂NR⁴⁹-, -NR⁵⁰SO₂- or -NR⁵¹- (wherein R⁴⁷, R⁴⁸, R⁴⁹, R⁵⁰ and R⁵¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁴² is as defined hereinbefore);
- 14) $C_{2-5}alkenylX^7R^{42}$ (wherein X⁷ represents -O-, -S-, -SO-, -SO₂-, -NR⁴³CO-, -CONR⁴⁴-, -SO₂NR⁴⁵-, -NR⁴⁶SO₂- or -NR⁴⁷- (wherein R⁵², R⁵³, R⁵⁴, R⁵⁵ and R⁵⁶ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁴² is as defined hereinbefore);
- 15) $C_{2-5}alkynylX^8R^{42}$ (wherein X⁸ represents -O-, -S-, -SO-, -SO₂-, -NR⁵⁷CO-, -CONR⁵⁸-, -SO₂NR⁵⁹-, -NR⁶⁰SO₂- or -NR⁶¹- (wherein R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰ and R⁶¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁴² is as defined hereinbefore);

- 16) $C_{1-3}alkylX^9C_{1-3}alkylR^{42}$ (wherein X^9 represents -O-, -S-, -SO-, -SO₂-, -NR⁶²CO-, -CONR⁶³-,
 $, -SO_2NR^{64}-$, -NR⁶⁵SO₂- or -NR⁶⁶- (wherein R⁶², R⁶³, R⁶⁴, R⁶⁵ and R⁶⁶ each independently
represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁴² is as defined hereinbefore); and
17) $C_{1-3}alkylX^9C_{1-3}alkylR^{32}$ (wherein X⁹ and R are as defined hereinbefore);
5 and R¹ and R⁴ may additionally be hydrogen.

In this specification the term 'alkyl' when used either alone or as a suffix includes straight chained, branched structures. Unless otherwise stated, these groups may contain up to 10, preferably up to 6 and more preferably up to 4 carbon atoms. Similarly the terms "alkenyl" and "alkynyl" refer to unsaturated straight or branched structures containing for 10 example from 2 to 10, preferably from 2 to 6 carbon atoms. Cyclic moieties such as cycloalkyl, cycloalkenyl and cycloalkynyl are similar in nature but have at least 3 carbon atoms. Terms such as "alkoxy" comprise alkyl groups as is understood in the art.

The term "halo" includes fluoro, chloro, bromo and iodo. References to aryl groups include aromatic carbocyclic groups such as phenyl and naphthyl. The term "heterocyclyl" 15 includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 8 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen. Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, 20 pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzoxazolyl, benzothienyl or benzofuryl.

"Heteroaryl" refers to those groups described above which have an aromatic character. The term "aralkyl" refers to aryl substituted alkyl groups such as benzyl.

Other expressions used in the specification include "hydrocarbyl" which refers to any structure comprising carbon and hydrogen atoms. For example, these may be alkyl, alkenyl, 25 alkynyl, aryl, heterocyclyl, alkoxy, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl.

The term "functional group" refers to reactive substituents such as nitro, cyano, halo, oxo, =CR⁷⁸R⁷⁹, C(O)_xR⁷⁷, OR⁷⁷, S(O)_yR⁷⁷, NR⁷⁸R⁷⁹, C(O)NR⁷⁸R⁷⁹, OC(O)NR⁷⁸R⁷⁹, =NOR⁷⁷, -NR⁷⁷C(O)_xR⁷⁸, -NR⁷⁷CONR⁷⁸R⁷⁹, -N=CR⁷⁸R⁷⁹, S(O)_yNR⁷⁸R⁷⁹ or -NR⁷⁷S(O)_yR⁷⁸ where R⁷⁷, R⁷⁸ and R⁷⁹ are independently selected from hydrogen or optionally substituted hydrocarbyl, 30 or R⁷⁸ and R⁷⁹ together form an optionally substituted ring which optionally contains further

heteroatoms such as S(O)_y, oxygen and nitrogen, x is an integer of 1 or 2, y is 0 or an integer of 1-3.

Suitable optional substituents for hydrocarbyl groups R⁷⁷, R⁷⁸ and R⁷⁹ include halo, perhaloalkyl such as trifluoromethyl, mercapto, hydroxy, carboxy, alkoxy, heteroaryl, 5 heteroaryloxy, alkenyloxy, alkynyloxy, alkoxyalkoxy, aryloxy (where the aryl group may be substituted by halo, nitro, or hydroxy), cyano, nitro, amino, mono- or di-alkyl amino, oximino or S(O)_y, where y is as defined above.

Suitable optional substituents for hydrocarbyl or heterocyclic groups R¹¹, R¹² and R¹³ include functional groups as defined above. Heterocyclic groups R¹¹, R¹² and R¹³ may further 10 be substituted by hydrocarbyl groups.

In particular, R⁶ and R⁷ are hydrogen.

Particular examples of R⁵ are groups OR¹¹ where R¹¹ is C₁₋₄alkyl.

Further examples of R⁵ are groups of formula NR¹²R¹³ where one of R¹² or R¹³ is 15 hydrogen and the other is optionally substituted hydrocarbyl, in particular optionally substituted C₁₋₆alkyl, optionally substituted aryl or optionally substituted heterocyclyl.

In particular, one of R¹² or R¹³ is hydrogen and the other is C₁₋₆alkyl optionally substituted with trifluoromethyl, C₁₋₃ alkoxy such as methoxy, cyano, thioC₁₋₄alkyl such as methylthio, or heterocyclyl optionally substituted with hydrocarbyl, such as indane, furan optionally substituted with C₁₋₄ alkyl such as methyl.

20 In another embodiment, one of R¹² or R¹³ is hydrogen and the other is an optionally substituted heterocyclic group such as pyridine, or a phenyl group optionally substituted with for example one or more groups selected from halo, nitro, alkyl such as methyl, or alkoxy such as methoxy.

Preferably R¹ and R⁴ are hydrogen.

25 Preferably R² and R³ are independently selected from a group -X¹R¹⁶ where X¹ is oxygen and R¹⁶ is as defined above. Particular groups R¹⁶ are those in group (1) above, especially alkyl such as methyl or halo substituted alkyl.

In a preferred embodiment, at least one group R² or R³, preferably R³, 30 comprises a chain of at least 3 and preferably at least 4 optionally substituted carbon atoms or heteroatoms such as oxygen, nitrogen or sulphur. Most preferably the chain is substituted by a polar group which assists in solubility.

Suitably R³ is a group XR¹¹. Preferably in this case, X¹ is oxygen and R¹¹ is selected from a group of formula (1) or (10) above. Particular groups R¹¹ are those in group (1) above, especially alkyl such as methyl or halo substituted alkyl, or those in group (10) above. In one preferred embodiment, at least one of R² or R³ is a group OC₁₋₅alkylR³³ and R³³ is a heterocyclic ring such as an N-linked morpholine ring such as 3-morpholinopropoxy.


5 Suitably R² is selected from, halo, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, -NR⁹R¹⁰ (wherein R⁹ and R¹⁰, which may be the same or different, each represents hydrogen or C₁₋₃alkyl), or a group -X¹R¹¹. Preferred examples of -X¹R¹¹ for R² include those listed above in relation to R³.

10 Other examples for R² and R³ include methoxy or 3,3,3-trifluoroethoxy.

Preferably X is NH or O and is most preferably NH.

Particular examples of groups R⁸ or R⁹ include hydrogen, halo, C₁₋₄alkoxy such as methoxy, or ethoxy, cyano, trifluoromethyl, or phenyl. Preferably R⁸ and R⁹ are hydrogen.

15 Suitably, at least one substituent is positioned at the 4-position on the phenyl. Thus in a preferred embodiment, the invention provides compounds of formula (IA)



(IA)

where all variable groups are as defined in relation to formula (I).

20 Suitable pharmaceutically acceptable salts of compounds of formula (I) include acid addition salts such as methanesulfonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations

or anions. Where the compound of formula (I) includes an acid functionality, salts may be base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, *N*-methylpiperidine, *N*-ethylpiperidine, procaine, dibenzylamine, *N,N*-dibenzylethylamine or 5 amino acids for example lysine. A preferred pharmaceutically acceptable salt is a sodium salt.

An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.

Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkyl esters such as 10 methyl or ethyl esters, C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxyethyl esters for example pivaloyloxyethyl, phthalidyl esters, C₃₋₈cycloalkoxy-carbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and 15 C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.


An *in vivo* hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 20 2,2-dimethylpropionyloxyethoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxy carbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.

25 Suitable amides are derived from compounds of formula (I) which have a carboxy group which is derivatised into an amide such as a N-C₁₋₆alkyl and N,N-di-(C₁₋₆alkyl)amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethylamide.










Esters which are not *in vivo* hydrolysable may be useful as intermediates in the 30 production of the compounds of formula (I).










Particular examples of compounds of formula (I) are set out in Table 1.









Table 1



Compd No.	R ²	R ³	X	R ⁵
1	OCH ₃	OCH ₃	NH	OCH ₂ CH ₃
2	OCH ₃	OCH ₃	O	OCH ₂ CH ₃
3	OCH ₃	OCH ₃	NH	NHC ₆ H ₅
4	OCH ₃	OCH ₃	NH	NHCH ₂ CH ₃
5	OCH ₃	OCH ₃	NH	
6	OCH ₃	OCH ₃	NH	
7	OCH ₃	OCH ₃	NH	
8	OCH ₃	OCH ₃	NH	
9	OCH ₃	OCH ₃	NH	

10	OCH ₃	OCH ₃	NH	
11	OCH ₃	OCH ₃	NH	
12	OCH ₃	OCH ₃	NH	
13	OCH ₃	OCH ₃	NH	
14	OCH ₃	OCH ₃	NH	
15	OCH ₃	OCH ₃	NH	NH(CH ₂) ₃ CH ₃
16	OCH ₃	OCH ₃	NH	
17	OCH ₃	OCH ₃	NH	
18	OCH ₃	OCH ₃	NH	
19	OCH ₃	OCH ₃	NH	
20	OCH ₃	OCH ₃	NH	


21	OCH ₃	OCH ₃	NH	
22	OCH ₃	OCH ₃	NH	
23	OCH ₃	OCH ₃	NH	
24	OCH ₃	OCH ₃	NH	
25	OCH ₃	OCH ₃	NH	
26	OCH ₃	OCH ₃	NH	
27	OCH ₃	OCH ₃	NH	
28	OCH ₃	OCH ₃	NH	
29	OCH ₃	OCH ₃	NH	

30	OCH ₃	OCH ₃	NH	
31	OCH ₃	OCH ₃	NH	
32	OCH ₃	O(CH ₂) ₃ N(C ₂ H ₅)C ₂ H ₅	NH	OH
33	OCH ₃	O(CH ₂) ₃ N(C ₂ H ₅)C ₂ H ₅	NH	
34	OCH ₃	O(CH ₂) ₃ N(C ₂ H ₅)C ₂ H ₅	NH	
35	OCH ₃	O(CH ₂) ₃ N(C ₂ H ₅)C ₂ H ₅	NH	
36	OCH ₃	O(CH ₂) ₃ N(C ₂ H ₅)C ₂ H ₅	NH	
37	OCH ₃	O(CH ₂) ₃ N(C ₂ H ₅)C ₂ H ₅	NH	
38	OCH ₃	O(CH ₂) ₃ N(C ₂ H ₅)C ₂ H ₅	NH	

39	OCH ₃		NH	
40	OCH ₃		NH	
41	OCH ₃		NH	NHCH ₂ CF ₃
42	OCH ₃		NH	NHCH ₂ CH(CH ₃) ₂
43	OCH ₃		NH	NHCH ₂ CH(CH ₃)(CH ₂) ₂ CH ₃
44	OCH ₃	OCH ₂ C ₆ H ₅	NH	OCH ₂ CH ₃
45	OCH ₃		NH	
46	OCH ₃		NH	
47	OCH ₃		NH	
48	OCH ₃		NH	
49	OCH ₃		NH	NHCH ₂ CH ₂ SCH ₃


50	OCH ₃		NH	OCH ₂ CH ₃	
----	------------------	--	----	----------------------------------	--

Compounds of formula (I) may be prepared by various methods which would be apparent from the literature. For example compounds of formula (I) may be prepared by
5 reacting a compound of formula (II)



(II)


10 where X, R¹, R², R³, R⁴, R⁸ and R⁹ are as defined in relation to formula (I) and R⁸⁵ is a leaving group, with a compound of formula (III)



15 where R⁵, R⁶ and R⁷ are as defined in relation to formula (I), and thereafter if desired or necessary, changing a group R⁵ to a different such group.

Suitable leaving groups for R⁸⁵ include halo such as chloro or iodo, mesylate and tosylate. The reaction is suitably effected in the presence of a base such as triethylamine, in an organic solvent such as acetonitrile or alcohol like isopropanol, at elevated temperatures, conveniently at the reflux temperature of the solvent.

Suitably the compound of formula (III) is prepared in situ, for example by reducing a compound of formula (IV)



(IV)

- 5 where R⁵, R⁶ and R⁷ are as defined in relation to formula (I), with a reducing agent such as tri(o-tolyl)phosphine in the presence of a catalyst such as a palladium catalyst, for instance palladium acetate.

Compounds of formula (II) and (IV) are either known compounds or they can be derived from known compounds by conventional methods.

- 10 The conversion of one group R⁵ to another such group can be readily effected using conventional chemistry. For example compounds of formula (I) where R⁵ is hydroxy can be converted to amides (where R⁵ is a group NR¹²R¹³) using known methods and in particular by reacting the compound of formula (I) where R⁵ is OH with an amine of formula HNR¹²R¹³ in the presence of a base such as a carbodiimide.

- 15 Compounds of formula (I) are inhibitors of aurora 2 kinase. As a result, these compounds can be used to treat disease mediated by these agents, in particular proliferative disease.

- 20 According to a further aspect of the invention there is provided a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, for use in a method of treatment of the human or animal body by therapy. In particular, the compounds are used in methods of treatment of proliferative disease such as cancer and in particular cancers such as colorectal or breast cancer where aurora 2 is upregulated.

- 25 According to a further aspect of the present invention there is provided a method for inhibiting aurora 2 kinase in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.

The invention also provides a pharmaceutical composition comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt, or an *in vivo* hydrolysable

ester thereof, in combination with at pharmaceutically acceptable carrier. Preferred compounds of formula (I) for use in the compositions of the invention are as described above.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation

products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or

5 condensation products of ethylene oxide with long chain aliphatic alcohols, for example

heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions

10 may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by

20 the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of

25 oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and

30 condensation products of the said partial esters with ethylene oxide such as polyoxyethylene

sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art.

Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30 μ or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.

Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on Formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the Formula I are useful in treating diseases or medical conditions which are due alone or in part to the effects of aurora 2 kinase.

In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred.

A further aspect of the invention comprises a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, for use in the preparation of a medicament for the treatment of proliferative disease. Preferred compounds of formula (I) for this purpose are as described above.

The following Examples illustrate the invention.

Example 1 - Preparation of Compound No. 1 in Table 1

Palladium (II) acetate (303 mg, 1.35 mmol) was added to a solution of 4-(4-

5 iodoanilino)-6,7-dimethoxyquinazoline (6.00g, 13.5 mmol), ethyl acrylate (1.35 g, 13.5 mmol) and tri(o-tolyl)phosphine (821 mg, 2.70 mmol) in a mixture of triethylamine (60 ml)

and acetonitrile (200 ml) and the reaction heated at reflux for 20 hours under an inert atmosphere. The reaction was cooled to ambient temperature, poured into water (600 ml), diluted with ethyl acetate (200 ml) and filtered through celite. The organic layer was

10 separated, the aqueous was extracted with ethyl acetate (2 x 200 ml) and the combined organic layers were dried over magnesium sulphate before solvent evaporation *in vacuo*. Purification by flash chromatography on silica gel, eluting with ethyl acetate, yielded 4-(4-(2-carboethoxy)ethenyl)anilino)-6,7-dimethoxyquinazoline (4.36 g, 85 % yield) as a yellow solid:

15 $^1\text{H-NMR}$ (DMSO d_6) : 9.6 (s, 1H), 8.5 (s, 1H), 7.9 (d, 2H), 7.85 (s, 1H), 7.75 (d, 2H), 7.65 (d, 1H), 7.2 (s, 1H), 6.5 (d, 1H), 4.2 (q, 2H), 4.0 (s, 3H), 3.9 (s, 3H), 1.25 (t, 3H) :
MS (-ve ESI) : 378 (M-H)⁻,
MS (+ve ESI) : 380 (M+H)⁺.

4-Chloro-6,7-dimethoxyquinazoline, used as the starting material was obtained as follows :

20 a) A mixture of 4,5-dimethoxyanthranilic acid (19.7g, 100 mmol) and formamide (10ml) was heated at 190 °C for 5 hours. The mixture was allowed to cool to approximately 80 °C and water (50ml) was added. The mixture was then allowed to stand at ambient temperature for 3 hours. Collection of the solid by suction filtration, followed by washing with water (2 x 50 ml) and drying in *vacuo*, yielded 6,7-dimethoxy-3,4-dihydroquinazolin-4-one (3.65g, 18 % yield) as a white solid.

$^1\text{H-NMR}$ (DMSO d_6) : 12.10 (s, 1H), 7.95 (s, 1H), 7.42 (s, 1H), 7.11 (s, 1H), 3.88 (s, 3H), 3.84 (s, 3H) :

MS (-ve ESI) : 205 (M-H)⁻.

30 b) Dimethylformamide (0.2 ml) was added dropwise to a solution of 6,7-dimethoxy-3,4-dihydro-quinazolin-4-one (10.0 g, 48.5 mmol) in thionyl chloride (200ml) and the reaction was heated at reflux for 6 hours. The reaction was cooled, excess thionyl chloride was removed *in vacuo* and the residue was azeotroped with toluene (2 x 50 ml) to remove the last

of the thionyl chloride. The residue was taken up in dichloromethane (550 ml), the solution was washed with saturated aqueous sodium hydrogen carbonate solution (2 x 250 ml) and the organic phase was dried over magnesium sulphate. Solvent evaporation *in vacuo* yielded 4-chloro-6,7-dimethoxyquinazoline (10.7 g, 98 % yield) as a white solid :

- 5 $^1\text{H-NMR}$ (DMSO d_6) : 8.86 (s, 1H), 7.42 (s, 1H), 7.37 (s, 1H), 4.00 (s, 3H), 3.98 (s, 3H) :
MS (+ve ESI) : 225 ($M-\text{H}^+$) .

Example 2 - Preparation of Compound No. 2 in Table 1

Palladium (II) acetate (11 mg, 0.05 mmol) was added to a solution of 4-(4-iodophenoxy)-6,7-dimethoxyquinazoline (205 mg, 0.50 mmol), ethyl acrylate (50 mg, 0.50 mmol) and tri(o-tolyl)phosphine (30 mg, 0.10 mmol) in a mixture of triethylamine (3 ml) and acetonitrile (9 ml) and the reaction heated at reflux for 16 hours under an inert atmosphere. The reaction was cooled to ambient temperature, poured into water (30 ml), diluted with ethyl acetate (25 ml) and filtered through celite. The organic layer was separated, the aqueous was extracted with ethyl acetate (2 x 25 ml) and the combined organic layers were dried over magnesium sulphate before solvent evaporation *in vacuo*. Purification by flash chromatography on silica gel, eluting with ethyl acetate / isohexane (1:1), yielded 4-(4-(2-carboethoxy)ethenyl)phenoxy)-6,7-dimethoxyquinazoline (130 mg, 68 % yield) as a cream solid :

- 20 $^1\text{H-NMR}$ (DMSO d_6) : 8.55 (s, 1H), 7.83 (d, 2H, $J = 8$ Hz), 7.70 (d, 1H, $J = 19.4$ Hz), 7.55 (s, 1H), 7.35 (d, 3H), 7.2 (s, 1H), 6.65 (d, 1H, $J = 19.4$ Hz), 4.20 (q, 2H), 4.02 (s, 3H), 3.95 (s, 3H), 1.25 (t, 3H) :
MS (+ve ESI) : 381 ($M+\text{H}^+$) .

4-(4-Iodophenoxy)-6,7-dimethoxyquinazoline, used as the starting material, was obtained as follows :

A solution of 4-chloro-6,7-dimethoxyquinazoline (224 mg, 1.00 mmol), potassium carbonate (152 mg, 1.10 mmol) and 4-iodophenol (244 mg, 1.10 mmol) in dimethylformamide (4 ml) was heated at 110 °C for 2 hours before the reaction was allowed to cool to ambient temperature. The reaction was poured into water and the solid which had precipitated was collected by suction filtration and washed with a mixture of diethyl ether (10 ml), ethyl acetate

(10 ml) and isohexane (10 ml). Drying of this material yielded, yielded the title compound (340 mg, 83 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 8.55 (s, 1H), 7.80 (d, 2H, J = 8 Hz), 7.50 (s, 1H), 7.35 (s, 1H), 7.15 (d, 2H, J = 8 Hz), 3.95 (s, 3H), 3.90 (s, 3H) :

5 MS (+ve ESI) : 409 (M-H)⁺.

Example 3 - Preparation of Compound No. 3 in Table 1

A mixture of 4-(4-(2-carboxy)ethenyl)anilino)-6,7-dimethoxyquinazoline (150 mg, 0.39 mmol), 4-(dimethylamino)pyridine (104 mg, 0.85 mmol), aniline (39 mg, 0.43 mmol) and
10 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (81 mg, 0.43 mmol) in dimethylacetamide (3.0 ml) was stirred at ambient temperature for 16 hours and then heated at 100 °C for 4 hours. The reaction was cooled, acidified by addition of 2.0H hydrochloric acid (7.0 ml, 14.0 mmol) and the precipitated solid collected by suction filtration. Drying *in vacuo* yielded the title compound (144 mg, 87 % yield) as a white solid :

15 ¹H-NMR (DMSO d₆) : 11.42 (s, 1H), 11.3 (s, 1H), 8.85 (s, 1H), 8.3 (s, 1H), 7.8 (d, 2H), 7.7 (dd, 4H), 7.6 (d, 1H), 7.3 (t, 3H), 7.05 (t, 1H), 6.9 (d, 1H), 4.05 (s, 3H), 3.95(s, 3H) :
MS (-ve ESI) : 425 (M-H)⁻,
MS (+ve ESI) : 427 (M+H)⁺.

4-(4-(2-carboxy)ethenyl)anilino)-6,7-dimethoxyquinazoline, used as the starting material, was
20 obtained as follows :

a) Palladium (II) acetate (303 mg, 1.35 mmol) was added to a solution of 4-(4-iodoanilino)-6,7-dimethoxyquinazoline (see below) (6.00g, 13.5 mmol), ethyl acrylate (1.35 g, 13.5 mmol) and tri(o-tolyl)phosphine (821 mg, 2.70 mmol) in a mixture of triethylamine (60 ml) and acetonitrile (200 ml) and the reaction heated at reflux for 20 hours under an inert atmosphere. The reaction was cooled to ambient temperature, poured into water (600 ml), diluted with ethyl acetate (200 ml) and filtered through celite. The organic layer was separated, the aqueous was extracted with ethyl acetate (2 x 200 ml) and the combined organic layers were dried over magnesium sulphate before solvent evaporation *in vacuo*. Purification by flash chromatography on silica gel, eluting with ethyl acetate, yielded 4-(4-(2-carboethoxy)ethenyl)anilino)-6,7-dimethoxyquinazoline (4.36 g, 85 % yield) as a yellow solid
25
30

¹H-NMR (DMSO d₆) : 9.6 (s, 1H), 8.5 (s, 1H), 7.9 (d, 2H), 7.85 (s, 1H), 7.75 (d, 2H), 7.65 (d, 1H), 7.2 (s, 1H), 6.5 (d, 1H), 4.2 (q, 2H), 4.0 (s, 3H), 3.9 (s, 3H), 1.25 (t, 3H) :
MS (-ve ESI) : 378 (M-H)⁻,
MS (+ve ESI) : 380 (M+H)⁺.

5 b) Aqueous sodium hydroxide solution (3.3N, 20.0 ml, 66.3 mmol) was added to a
solution of 4-(4-(2-carboethoxy)ethenyl)anilino)-6,7-dimethoxyquinazoline (8.38 g, 22.1
mmol) in ethanol (200 ml) and the reaction was heated at reflux for 16 hours. The reaction
was allowed to cool to ambient temperature, diethyl ether (200 ml) was added and the solid
material collected by suction filtration. The solid was taken up in ethanol (200 ml), acidified
10 by addition of 1.0N hydrochloric acid (100 ml, 100 mmol) and the solid collected by suction
filtration. Drying *in vacuo* yielded 4-(4-(2-carboxy)ethenyl)anilino)-6,7-
dimethoxyquinazoline (8.25 g, 97 % yield) as a yellow solid :

¹H-NMR (DMSO d₆) : 10.73 (s, 1H), 8.65 (s, 1H), 8.25 (s, 1H), 7.95 (d, 2H), 7.7 (d, 2H), 7.55
(d, 1H), 7.3 (s, 1H), 7.3 (s, 1H), 6.45 (d, 1H), 4.0 (s, 3H), 3.9 (s, 3H) :
15 MS (-ve ESI) : 350 (M-H)⁻,
MS (+ve ESI) : 352 (M+H)⁺.

c) As an alternative, a solution of 4-aminocinnamic acid (199 mg, 1.00 mmol) and 4-chloro-6,7-dimethoxyquinazoline (224 mg, 1.00 mmol) in isopropanol (200 ml) was heated at reflux for 3 hours before the reaction was allowed to cool to ambient temperature. The solid which had precipitated was collected by suction filtration and washed with diethyl ether (2 x 50 ml). Drying of this material yielded 4-(4-(2-carboxy)ethenyl)anilino)-6,7-dimethoxyquinazoline (350 mg, 90 % yield) as a yellow solid.

d) 4-(4-iodoanilino)-6,7-dimethoxyquinazoline, used as the starting material in step (a) was obtained as follows :

25 4-iodoaniline (4.89 g, 22.3 mmol) and 4-chloro-6,7-dimethoxyquinazoline (5.00 g, 22.3 mmol), in isopropanol (200 ml) was heated at reflux for 3 hours before the reaction was allowed to cool to ambient temperature. The solid which had precipitated was collected by suction filtration and washed with diethyl ether (2 x 50 ml). Drying of this material yielded 4-(4-iodoanilino)-6,7-dimethoxyquinazoline (9.38 g, 95 % yield) as a white solid :

30 ¹H-NMR (DMSO d₆) : 11.33 (s, 1H), 8.81 (s, 1H), 8.30 (s, 1H), 7.80 (s, 1H), 7.55 (d, 2H), 7.30 (s, 1H), 4.02 (s, 3H), 3.93 (s, 3H) :

MS (-ve ESI) : 406 (M-H)⁻,

MS (+ve ESI) : 408 (M+H)⁺.

Example 4 - Preparation of Compound No. 4 in Table 1

5 An analogous reaction to that described in example 3, but starting with ethylamine

hydrochloride (35 mg, 0.43 mmol) (in place of the aniline), yielded the title compound (109 mg, 74 % yield) as a pale-yellow solid :

¹H-NMR (DMSO d₆) : 9.50 (s, 1H), 8.50 (s, 1H), 7.91-8.00 (m, 3H), 7.85 (s, 1H), 7.50-7.60 (m, 2H) ; 7.40 (d, 1H), 7.20 (s, 1H), 6.50 (d, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 3.50-3.80 (m, 8H),

10 3.30 (m, 2H), 1.05 (m, 3H) :

MS (-ve ESI) : 377 (M-H)⁻,

MS (+ve ESI) : 379 (M+H)⁺.

Example 5 - Preparation of Compound No. 5 in Table 1

15 An analogous reaction to that described in example 3, but starting with morpholine (37 mg, 0.43 mmol) (in place of the aniline), yielded the title compound (125 mg, 77 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 11.17 (s, 1H), 8.80 (s, 1H), 8.25 (s, 1H), 7.80 (s, 4H), 7.50 (d, 1H) ; 7.30 (s, 1H), 7.20 (s, 1H), 4.00 (s, 3H), 3.95 (s, 3H), 3.50-3.80 (m, 8H) :

20 MS (-ve ESI) : 419 (M-H)⁻.

Example 6 - Preparation of Compound No. 6 in Table 1

A solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (63 mg, 0.33 mmol) and 4-(dimethylamino)pyridine (73 mg, 0.60 mmol) in dimethylacetamide (3.0 ml) was added to methylaniline (35 mg, 0.33 mmol) and 4-(4-(2-carboxyethenyl)anilino)-6,7-dimethoxyquinazoline (116 mg, 0.30 mmol). The reaction was stirred at ambient temperature for 48 hours and then heated at 100 °C for 4 hours before being cooled to ambient temperature. Brine (10 ml) was added and the reaction allowed to stand for 16 hours before the solid was collected by suction filtration (analogous reactions which failed 30 to yield a solid precipitate were extracted with dichloromethane (2 x 5 ml) and the

dichloromethane layer evaporated *in vacuo* to give a solid product). Drying *in vacuo* yielded the title compound (77.4 mg, 59 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 10.1 (s, 1H), 9.65 (s, 1H), 8.65 (s, 1H), 8.0 (d, 2H), 7.90 (s, 1H), 7.70 (d, 2H), 7.65 (d, 2H), 7.55 (d, 1H); 7.25 (s, 1H), 7.15 (d, 2H), 6.8 (d, 1H), 4.02 (s, 3H), 3.95 (s, 3H), 2.3 (s, 3H) :

MS (+ve ESI) : 441 (M+H)⁺.

Example 7 - Preparation of Compound No. 7 in Table 1

An analogous reaction to that described in example 6, but starting with 1,3-dimethylbutylamine (33 mg, 0.33 mmol) yielded the title compound (97.2 mg, 75 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.65 (s, 1H), 8.65 (s, 1H), 7.95-7.90 (m, 3H), 7.85 (d, 1H), 7.60 (d, 2H), 7.40 (d, 1H); 7.25 (s, 1H), 6.55 (d, 1H), 4.02 (s, 4H), 3.95 (s, 3H), 1.7-1.6 (m, 1H), 1.5-1.4 (m, 1H), 1.3-1.2 (m, 1H), 1.1 (d, 3H), 0.9-0.85 (m, 6H) :

MS (+ve ESI) : 435 (M+H)⁺.

Example 8 - Preparation of Compound No. 8 in Table 1

An analogous reaction to that described in example 6, but starting with 2-chlorobenzylamine (47 mg, 0.33 mmol) yielded the title compound (97.1 mg, 68 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.70 (s, 1H), 8.65-8.6 (m, 1H), 8.55 (s, 1H), 7.95 (d, 2H), 7.90 (s, 1H), 7.60 (d, 2H), 7.50-7.45 (m, 2H); 7.42-7.30 (m, 3H), 7.25 (s, 1H), 6.70 (d, 1H), 4.50 (d, 2H), 4.02 (s, 3H), 3.95 (s, 3H) :

MS (+ve ESI) : 475 (M+H)⁺.

25

Example 9 - Preparation of Compound No. 9 in Table 1

An analogous reaction to that described in example 6, but starting with 3-amino-1,2-propanediol (30 mg, 0.33 mmol) yielded the title compound (72.7 mg, 57 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.62 (s, 1H), 8.55 (s, 1H), 8.10-8.05 (m, 1H), 7.95 (d, 2H), 7.90 (s, 1H), 7.60 (d, 2H), 7.45 (d, 2H); 7.25 (s, 1H), 6.70 (d, 1H), 4.85 (d, 1H), 4.60 (t, 1H), 4.02 (s, 3H), 3.95 (s, 3H), 3.40-3.30 (m, 4H) :
 MS (+ve ESI) : 425 (M+H)⁺.

5

Example 10 - Preparation of Compound No. 10 in Table 1

An analogous reaction to that described in example 6, but starting with isobutylamine (24 mg, 0.33 mmol) yielded the title compound (87.5 mg, 72 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.62 (s, 1H), 8.55 (s, 1H), 8.10-8.05 (m, 1H), 7.95 (d, 2H), 7.90 (s, 1H), 7.60 (d, 2H), 7.45 (d, 1H); 7.25 (s, 1H), 6.65 (d, 1H), 4.02 (s, 3H), 3.95 (s, 3H), 3.10-3.0 (m, 2H), 1.80-1.70 (m, 1H), 0.92 (s, 3H), 0.88 (s, 3H) :
 MS (+ve ESI) : 407 (M+H)⁺.

Example 11 - Preparation of Compound No. 11 in Table 1

An analogous reaction to that described in example 6, but starting with 2-methyl-1-amylamine (33 mg, 0.33 mmol) yielded the title compound (88.4 mg, 75 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.65(s, 1H), 8.55 (s, 1H), 8.05-8.0 (m, 1H), 7.97 (d, 2H), 7.95 (s, 1H), 7.60 (d, 2H), 7.45 (d, 1H); 7.25 (s, 1H), 6.65 (d, 1H), 4.0 (s, 3H), 3.95 (s, 3H), 3.20-3.10 (m, 1H), 3.07-2.95 (m, 1H), 1.70-1.60 (m, 1H), 1.40-1.20 (m, 3H), 1.15-1.05 (m, 1H), 0.9-0.85 (m, 6H) :
 MS (+ve ESI) : 435 (M+H)⁺.

Example 12 - Preparation of Compound No. 12 in Table 1

An analogous reaction to that described in example 6, but starting with 2-methoxyethylamine (25 mg, 0.33 mmol) yielded the title compound (87 mg, 71 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.68 (s, 1H), 8.55 (s, 1H), 8.20-8.10 (m, 1H), 7.95 (d, 2H), 7.90 (s, 1H), 7.60 (d, 2H), 7.45 (d, 1H); 7.25 (s, 1H), 6.65 (d, 1H), 4.0 (s, 3H), 3.95 (s, 3H), 3.50-3.35 (m, 4H), 3.30 (s, 3H) :
 MS (+ve ESI) : 409 (M+H)⁺.

Example 13 - Preparation of Compound No. 13 in Table 1

An analogous reaction to that described in example 6, but starting with propargylamine (18 mg, 0.33 mmol) yielded the title compound (8.4 mg, 7 % yield) as a white solid :

- 5 $^1\text{H-NMR}$ (DMSO d₆) : 9.60 (s, 1H), 8.52 (s, 1H), 8.50-8.45 (m, 1H), 7.95 (d, 2H), 7.90 (s, 1H),
 7.62 (d, 2H), 7.50 (d, 1H); 7.25 (s, 1H), 6.70 (d, 1H), 4.05-4.0 (m, 2H), 3.98 (s, 3H), 3.95 (s,
 3H), 3.15 (s, 1H) :
 MS (+ve ESI) : 389 (M+H)⁺.

10 Example 14 - Preparation of Compound No. 14 in Table 1

An analogous reaction to that described in example 6, but starting with 3-(dimethylamino)-propylamine (34 mg, 0.33 mmol) yielded the title compound (58.7 mg, 45 % yield) as a white solid :

- 15 $^1\text{H-NMR}$ (DMSO d₆) : 9.60 (s, 1H), 8.55 (s, 1H), 8.05 (t, 1H), 7.96 (d, 2H), 7.88 (s, 1H), 7.60
 (d, 2H), 7.40 (d, 1H); 7.25 (s, 1H), 6.70 (d, 1H), 4.0 (s, 3H), 3.95 (s, 3H), 3.25-3.20 (m, 2H),
 2.30-2.20 (m, 2H), 2.15 (s, 6H), 1.65-1.55 (m, 2H) :
 MS (+ve ESI) : 436 (M+H)⁺.

Example 15 - Preparation of Compound No. 15 in Table 1

- 20 An analogous reaction to that described in example 6, but starting with butylamine (24 mg, 0.33 mmol) yielded the title compound (96.4 mg, 79 % yield) as a white solid :

$^1\text{H-NMR}$ (DMSO d₆) : 9.65 (s, 1H), 8.52 (s, 1H), 8.05 (t, 1H), 7.95 (s, 1H), 7.92 (d, 2H), 7.60
 (d, 2H), 7.42 (d, 1H); 7.23 (s, 1H), 6.70 (d, 1H), 4.0 (s, 3H), 3.95 (s, 3H), 3.25-3.15 (m, 2H),
 1.52-1.42 (m, 2H), 1.38-1.3 (m, 2H), 0.95-0.90 (m, 3H) :

- 25 MS (+ve ESI) : 407 (M+H)⁺.

Example 16 - Preparation of Compound No. 16 in Table 1

- 30 An analogous reaction to that described in example 6, but starting with 2-amino-1-methoxypropane (29 mg, 0.33 mmol) yielded the title compound (52.6 mg, 42 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.70 (s, 1H), 8.55 (s, 1H), 8.0-7.95 (m, 3H), 7.95 (s, 1H), 7.60 (d, 2H), 7.40 (d, 1H); 7.21 (s, 1H), 6.70 (d, 1H), 4.12-4.02 (m, 1H), 4.0 (s, 3H), 3.98 (s, 3H), 3.40-3.22 (m, 5H), 1.11 (d, 3H) :
 MS (+ve ESI) : 423 (M+H)⁺.

5

Example 17 - Preparation of Compound No. 17 in Table 1

An analogous reaction to that described in example 6, but starting with 3-methylaniline (35 mg, 0.33 mmol) yielded the title compound (88.8 mg, 67 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 10.1 (s, 1H), 9.65 (s, 1H), 8.55 (s, 1H), 8.0 (d, 2H), 7.90 (s, 1H), 7.67 (d, 2H), 7.60 (s, 1H), 7.55-7.50 (m, 2H); 7.30-7.20 (m, 2H), 6.95-6.90 (m, 1H), 6.8 (d, 1H), 4.02 (s, 3H), 3.95 (s, 3H), 2.35 (s, 3H) :
 MS (+ve ESI) : 441 (M+H)⁺.

Example 18 - Preparation of Compound No. 18 in Table 1

15 An analogous reaction to that described in example 6, but starting with 3-methylcyclohexylamine (37 mg, 0.33 mmol) yielded the title compound (111 mg, 83 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.60 (s, 1H), 8.51 (s, 1H), 7.84-7.96 (m, 4H), 7.57 (d, 2H, J = 8 Hz), 7.40 (d, 1H, J = 16 Hz), 7.21 (s, 1H), 6.55 (d, 1H, J = 16 Hz), 4.00 (s, 3H), 3.96 (s, 3H), 3.65 (m, 1H), 1.40-1.84 (m, 7H), 1.20-1.37 (m, 1H), 1.00-1.15 (m, 1H), 0.93 (d, 3H, J = 7 Hz), 0.77-0.91 (m, 1H) :
 MS (+ve ESI) : 447 (M+H)⁺.

Example 19 - Preparation of Compound No. 19 in Table 1

25 An analogous reaction to that described in example 6, but starting with 2-aminoindan hydrochloride (44 mg, 0.33 mmol) yielded the title compound (117.8 mg, 84 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.75 (s, 1H), 8.50 (s, 1H), 8.40 (d, 1H), 8.0-7.90 (m, 3H), 7.60 (d, 2H), 7.45 (d, 1H), 7.30-7.25 (m, 2H), 7.20 (s, 1H), 7.15-7.10 (m, 2H), 6.60 (d, 1H), 4.75-4.65 (m, 1H), 4.02 (s, 3H), 3.95 (s, 3H), 3.30-3.20 (m, 2H), 2.90-2.80 (m, 2H) :
 MS (+ve ESI) : 467 (M+H)⁺.

Example 20 - Preparation of Compound No. 20 in Table 1

An analogous reaction to that described in example 6, but starting with 4-chlorotetrahydro-3-thiopheneamine-1,1-dioxide hydrochloride (55 mg, 0.33 mmol) yielded the title compound (88.2 mg, 58 % yield) as a white solid :

5 $^1\text{H-NMR}$ (DMSO d₆) : 9.61 (s, 1H), 8.77 (d, 1H, J = 6 Hz), 8.52 (s, 1H), 7.94 (d, 2H, J = 8 Hz),
7.87 (s, 1H), 7.62 (d, 2H, J = 8 Hz), 7.50 (d, 1H, J = 16 Hz), 7.21-7.28 (m, 2H), 7.25 (s, 1H),
6.91 (m, 1H), 6.57 (d, 1H, J = 16 Hz), 5.27-5.33 (m, 1H), 4.00 (s, 3H), 3.97 (s, 3H), 3.78 (dd,
1H, J = 5,8 Hz), 3.11 (dd, 1H, J = 5,8 Hz) :

10 MS (+ve ESI) : 504 (M+H)⁺.

Example 21 - Preparation of Compound No. 21 in Table 1

An analogous reaction to that described in example 6, but starting with 5-methyl-2-(aminomethyl)furan (37 mg, 0.33 mmol) yielded the title compound (99.2 mg, 74 % yield) as
15 a white solid :

16 $^1\text{H-NMR}$ (DMSO d₆) : 9.60 (s, 1H), 8.55 (s, 1H), 8.55 (t, 1H), 7.90 (d, 2H), 7.88 (s, 1H), 7.60
(d, 2H), 7.45 (d, 1H), 7.25 (s, 1H), 6.63 (d, 1H), 6.20 (d, 1H), 6.0 (d, 1H), 4.35 (d, 2H), 4.02 (s,
3H), 3.95 (s, 3H), 2.25 (s, 3H) :

17 MS (+ve ESI) : 445 (M+H)⁺.

20

Example 22 - Preparation of Compound No. 22 in Table 1

An analogous reaction to that described in example 6, but starting with cyclopropylamine (18 mg, 0.33 mmol) yielded the title compound (79.4 mg, 68 % yield) as a white solid :

25 $^1\text{H-NMR}$ (DMSO d₆) : 9.60 (s, 1H), 8.55 (s, 1H), 8.15 (d, 1H), 7.95 (d, 2H), 7.90 (s, 1H), 7.60
(d, 2H), 7.40 (d, 1H), 7.22 (s, 1H), 6.55 (d, 1H), 4.02 (s, 3H), 3.95 (s, 3H), 2.90-2.80 (m, 1H),
0.75-0.70 (m, 2H), 0.55-0.50 (m, 2H) :

30 MS (+ve ESI) : 391 (M+H)⁺.

30

Example 23 - Preparation of Compound No. 23 in Table 1

An analogous reaction to that described in example 6, but starting with cyclobutylamine (23 mg, 0.33 mmol) yielded the title compound (81.6 mg, 67 % yield) as a white solid :

- 5 $^1\text{H-NMR}$ (DMSO d_6) : 9.58 (s, 1H), 8.50 (s, 1H), 8.30 (d, 1H), 7.95 (d, 2H), 7.90 (s, 1H), 7.60
 (d, 2H), 7.40 (d, 1H), 7.22 (s, 1H), 6.55 (d, 1H), 4.40-4.30 (m, 1H), 4.02 (s, 3H), 3.95 (s, 3H),
 2.30-2.20 (m, 2H), 2.0-1.90 (m, 2H), 1.75-1.65 (m, 2H) :
 MS (+ve ESI) : 405 ($M+\text{H}^+$)⁺.

10 Example 24 - Preparation of Compound No. 24 in Table 1

An analogous reaction to that described in example 6, but starting with cyclopentylamine (28 mg, 0.33 mmol) yielded the title compound (81.6 mg, 65 % yield) as a white solid :

- 15 $^1\text{H-NMR}$ (DMSO d_6) : 9.60 (s, 1H), 8.55 (s, 1H), 8.0 (d, 1H), 7.92 (d, 2H), 7.90 (s, 1H), 7.60
 (d, 2H), 7.40 (d, 1H), 7.22 (s, 1H), 6.55 (d, 1H), 4.20-4.10 (m, 1H), 4.02 (s, 3H), 3.95 (s, 3H),
 1.95-1.85 (m, 2H), 1.85-1.75 (m, 2H), 1.60-1.50 (m, 2H), 1.50-1.40 (m, 2H) :
 MS (+ve ESI) : 419 ($M+\text{H}^+$)⁺.

20 Example 25 - Preparation of Compound No. 25 in Table 1

An analogous reaction to that described in example 6, but starting with cyclohexylamine (36 mg, 0.33 mmol) yielded the title compound (94.7 mg, 73 % yield) as a white solid :

- 25 $^1\text{H-NMR}$ (DMSO d_6) : 9.60 (s, 1H), 8.55 (s, 1H), 7.95-7.92 (m, 3H), 7.90 (s, 1H), 7.60 (d,
 2H), 7.40 (d, 1H), 7.22 (s, 1H), 6.60 (d, 1H), 4.02 (s, 3H), 3.95 (s, 3H), 3.55-3.70 (m, 1H),
 1.85-1.78 (m, 2H), 1.75-1.65 (m, 2H), 1.60-1.50 (m, 1H), 1.40-1.15 (m, 5H) :
 MS (+ve ESI) : 433 ($M+\text{H}^+$)⁺.

30 Example 26 - Preparation of Compound No. 26 in Table 1

An analogous reaction to that described in example 6, but starting with piperidine (28 mg, 0.33 mmol) yielded the title compound (89.9 mg, 72 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.55 (s, 1H), 8.5 (s, 1H), 7.9 (d, 2H), 7.85 (s, 1H), 7.7 (d, 2H), 7.45 (d, 1H, J=16Hz), 7.2 (s, 1H), 7.15 (d, 1H, J=16Hz), 3.98 (s, 3H), 3.93 (s, 3H), 3.65 (m, 2H), 3.55 (m, 2H), 1.63 (m, 2H), 1.5 (m, 4H) :

MS (+ve ESI) : 419 (M+H)⁺.

5

Example 27 - Preparation of Compound No. 27 in Table 1

An analogous reaction to that described in example 6, but starting with 3-aminopyridine (31 mg, 0.33 mmol) yielded the title compound (41.5 mg, 32 % yield) as a white solid :

- 10 ¹H-NMR (DMSO d₆) : 10.39 (s, 1H), 9.6 (s, 1H), 8.85 (m, 1H), 8.55 (s, 1H), 8.3 (m, 1H), 8.15 (m, 1H), 8.0 (d, 2H), 7.88 (s, 1H), 7.7 (d, 2H), 7.65 (d, 1H, J = 16 Hz); 7.4 (m, 1H), 7.25 (s, 1H), 6.8 (d, 1H J = 16 Hz), 3.99 (s, 3H), 3.95 (s, 3H) :
 MS (+ve ESI) : 428 (M+H)⁺.

15 Example 28 - Preparation of Compound No. 28 in Table 1

An analogous reaction to that described in example 6, but starting with 2-methoxyaniline (41 mg, 0.33 mmol) yielded the title compound (36.9 mg, 27 % yield) as a white solid :

- 20 ¹H-NMR (DMSO d₆) : 9.65 (s, 1H), 9.28 (s, 1H), 8.55 (s, 1H), 8.2 (m, 1H), 7.95 (d, 2H), 7.9 (s, 1H), 7.65 (d, 2H), 7.55 (d, 1H, J=16Hz), 7.23 (s, 1H), 7.13 (d, 1H, J=16Hz), 7.08 (m, 2H), 6.95 (m, 1H), 4.0 (s, 3H), 3.98 (s, 3H), 3.9 (s, 3H) :
 MS (+ve ESI) : 457 (M+H)⁺.

Example 29 - Preparation of Compound No. 29 in Table 1

- 25 An analogous reaction to that described in example 6, but starting with 2-methylaniline (35 mg, 0.33 mmol) yielded the title compound (90.2 mg, 68 % yield) as a white solid :

- ¹H-NMR (DMSO d₆) : 9.65 (s, 1H), 9.5 (s, 1H), 8.55 (s, 1H), 7.95 (d, 2H), 7.88 (s, 1H), 7.68 (d, 2H), 7.6 (m, 1H), 7.55 (d, 1H, J=16Hz), 7.2 (m, 3H), 7.1 (m, 1H), 6.95 (d, 1H, J=16Hz), 4.0 (s, 3H), 3.95 (s, 3H), 2.3 (s, 3H) :
 30 MS (+ve ESI) : 441 (M+H)⁺.

Example 30 - Preparation of Compound No. 30 in Table 1

An analogous reaction to that described in example 6, but starting with 3-methoxyaniline (41 mg, 0.33 mmol) yielded the title compound (75.1 mg, 55 % yield) as a white solid :

- 5 ¹H-NMR (DMSO d₆) : 10.15 (s, 1H), 9.65 (s, 1H), 8.55 (s, 1H), 7.95 (d, 2H), 7.9 (s, 1H), 7.65
 (d, 2H), 7.6 (d, 1H, J=16Hz), 7.43 (s, 1H), 7.2 (m, 3H), 6.78 (d, 1H, J=16Hz), 6.65 (m, 1H),
 4.0 (s, 3H), 3.98 (s, 3H), 3.78 (s, 3H) :
 MS (+ve ESI) : 457 (M+H)⁺.

10 Example 31 - Preparation of Compound No. 31 in Table 1

An analogous reaction to that described in example 6, but starting with 4-chloroaniline (42 mg, 0.33 mmol) yielded the title compound (76.7 mg, 56 % yield) as a white solid :

- 15 ¹H-NMR (DMSO d₆) : 10.35 (s, 1H), 9.7 (s, 1H), 8.55 (s, 1H), 8.0 (d, 2H), 7.9 (s, 1H), 7.75
 (d, 2H), 7.65 (d, 2H), 7.6 (d, 1H, J=16Hz), 7.4 (d, 2H), 7.25 (s, 1H), 6.8 (d, 1H, J=16Hz), 4.0
 (s, 3H), 3.95 (s, 3H) :
 MS (+ve ESI) : 461 (M+H)⁺.

Example 32 - Preparation of Compound No. 32 in Table 1

A solution 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (6.90 g, 20.0 mmol) and 4-aminocinnamic acid hydrochloride (4.16 g, 20.8 mmol) in isopropanol (100 ml) was heated at reflux for 3 hours before the reaction was allowed to cool to ambient temperature. The solid which had precipitated was collected by suction filtration and washed with diethyl ether (2 x 50 ml). Drying of this material yielded the title compound (7.28 g, 68 % yield) as a white solid :

- 25 ¹H-NMR (DMSO d₆) : 11.58 (s, 1H), 11.14 (s, 1H), 8.85 (s, 1H), 8.45 (s, 1H), 7.8 (dd, 4H),
 7.6 (d, 1H, J= 16Hz), 7.45 (s, 1H), 6.55 (d, 1H, J= 16 Hz), 4.3 (t, 2H), 4.05 (s, 3H), 3.95 (m,
 2H), 3.8 (m, 2H), 3.5 (m, 2H), 3.3 (m, 2H), 3.1 (m, 2H), 2.3 (m, 2H) :
 MS (+ve ESI) : 465 (M+H)⁺.

4-Chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline, used as the starting material, was

- 30 obtained as follows :

a) A mixture of morpholine (261 ml, 3.00 mol) and 1-bromo-3-chloropropane (148 ml, 1.50 mol) in toluene (900 ml) was stirred for 18 hours at ambient temperature. Additional 1-bromo-3-chloropropane (25 ml, 0.25 mol) was added, the reaction was stirred for a further 1 hour and then filtered to remove the precipitated solid before the filtrate was concentrated *in vacuo*. Distillation of the crude oil yielded N-(3-chloropropyl)-morpholine (119.3 g, 49 % yield) as the fraction boiling at 70 - 80 °C / 2.6 mmHg :

¹H-NMR (DMSO d₆) : 3.65 (t, 2H), 3.55 (m, 4H), 2.4 (t, 2H), 2.39 (m, 4H), 1.85 (m, 2H) :
MS (+ve ESI) : 164 (M+H)⁺.

b) N-(3-Chloropropyl)morpholine (90 g, 0.55 mol) was added dropwise, over 30 minutes, to a solution of ethyl vanillate (98 g, 0.50 mol) and powdered potassium carbonate (104 g, 0.75 mol) in dimethylformamide (300 ml) at 80 °C. The reaction was heated at 80 °C for 90 minutes, cooled to ambient temperature, filtered and the filtrate concentrated *in vacuo*. The crude product was taken up in diethyl ether (1000 ml), filtered and washed with water (2 x 200 ml) and brine (200 ml). Solvent evaporation in vacuo yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate (161.5 g, 100 % yield) as a pale yellow oil which crystallised on standing to afford a pale yellow solid :

¹H-NMR (DMSO d₆) : 7.55 (dd, 1H), 7.4 (d, 1H), 7.05 (d, 1H), 4.3 (q, 2H), 4.05 (t, 2H), 3.8 (s, 3H), 3.55 (m, 4H), 2.4 (t, 2H), 2.35 (m, 4H), 1.9 (m, 2H), 1.3 (t, 3H) :
MS (-ve ESI) : 324 (M-H)⁻,

c) Concentrated sulphuric acid (110 ml) and concentrated nitric acid (19.0 ml, 0.289 mol) were added cautiously, over a 50 minute period, to a two-phase system containing a stirred solution of ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate (76.5 g, 0.237 mol) in dichloromethane (600 ml), acetic acid (300 ml) and water (70 ml) at 5 °C. The reaction was allowed to warm to ambient temperature over 18 hours, the aqueous phase was separated, and the aqueous phase was taken to pH 9 by addition of 40% aqueous sodium hydroxide solution (775 ml). Extraction of the aqueous phase with dichloromethane (3 x 600 ml) and subsequent solvent evaporation *in vacuo* yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-nitrobenzoate (141.3 g, 86 % yield) as a yellow gum :

¹H-NMR (CDCl₃) : 7.50 (s, 1H), 7.10 (s, 1H), 4.40 (q, 2H), 4.20 (t, 2H), 4.00 (s, 3H), 3.70 (m, 4H), 2.50 (t, 2H), 2.45 (m, 4H), 2.05 (m, 2H), 1.40 (t, 3H) :
MS (+ve ESI) : 369 (M+H)⁺.

d) A suspension of ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-nitrobenzoate (132.2 g, 359 mmol) and 10% palladium on carbon (3.0 g) in a mixture of ethanol (200 ml) and ethyl acetate (2000 ml) was stirred under an atmosphere of hydrogen for 18 hours. Removal of the catalyst by filtration, followed by solvent evaporation *in vacuo* yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate (122 g, 100 % yield) as a brown oil :

¹H-NMR (DMSO d₆) : 7.15 (s, 1H), 6.40 (s, 2H), 6.35 (s, 1H), 4.20 (q, 2H), 3.95 (t, 2H), 3.65 (s, 3H), 3.55 (m, 4H), 2.40 (t, 2H), 2.35 (m, 4H), 1.85 (m, 2H), 1.25 (t, 3H) ;
 MS (-ve ESI) : 337 (M-H)⁻,
 MS (+ve ESI) : 339 (M+H)⁺.

10 e) A solution of ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate (130 g, 384 mmol) in formamide (280 ml) was heated at 180 °C for 3 hours, during which time a small amount (25 ml) of liquid distilled out of the reaction. The reaction was cooled to 125 °C and the excess formamide was evaporated *in vacuo*. Trituration of the solid residue with isopropanol (100 ml), followed by drying *in vacuo*, yielded 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (83.0 g, 68 % yield) as a pale brown solid :

¹H-NMR (DMSO d₆) : 12.0 (s, 1H), 7.95 (s, 1H), 7.45 (s, 1H), 7.1 (s, 1H), 4.15 (t, 2H), 3.85 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.35 (m, 4H), 1.9 (m, 2H) :
 MS (-ve ESI) : 318 (M-H)⁻,
 MS (+ve ESI) : 320 (M+H)⁺.

20 f) Dimethylformamide (2.0 ml) was added dropwise to a solution of 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydro-quinazolin-4-one (83.0 g, 261 mmol) in thionyl chloride (700ml) and the reaction was heated at reflux for 3.5 hours. The reaction was cooled, excess thionyl chloride was removed *in vacuo*, the residue was taken up in water (500 ml) and this aqueous solution was taken to pH 9 by addition of saturated aqueous sodium bicarbonate solution (300 ml). The aqueous phase was extracted with dichloromethane (2 x 400 ml), the organic solution was washed with brine (400 ml) and the solvents were removed *in vacuo*. Trituration of the solid residue with ethyl acetate (150 ml), followed by drying *in vacuo*, yielded 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (53 g, 60 % yield) as a pale brown solid :

30 ¹H-NMR (CDCl₃) : 8.85 (s, 1H), 7.39 (s, 1H), 7.38 (s, 1H), 4.3 (t, 2H), 4.05 (s, 3H), 3.7 (m, 4H), 2.6 (t, 2H), 2.5 (m, 4H), 2.1 (m, 2H) :

MS (+ve ESI) : 338 (M+H)⁺.

Example 33 - Preparation of Compound No. 33 in Table 1

O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluoro-phosphate

5 (HATU) (192 mg, 0.50 mmol) was added to a suspension 4-(4-(2-carboxyethenyl)phenyl)-6-methoxy-7-(3-morpholinopropoxy)quinazoline (232 mg, 0.50 mmol) in dimethylformamide (4.5 ml). After 5 minutes, cyclohexylmethylamine (56.9 mg, 0.50 mmol) was added and the reaction heated at 50 °C for 16 hours. The reaction was cooled, poured into water (10 ml) and diethyl ether (5 ml) was added. The solid which precipitated was collected by suction filtration

10 and washed with water (10 ml) and diethyl ether (10ml). Drying of the solid *in vacuo* yielded the title compound (149.9 mg, 59 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.55 (s, 1H), 8.45 (s, 1H), 8.0 (t, 1H), 7.9 (d, 2H), 7.85 (s, 1H), 7.65 (d,2H), 7.4 (d, 1H, J= 16Hz), 7.2 (s, 1H), 6.6 (d, 1H, J= 16Hz), 4.2 (t, 2H), 4.0 (s, 3H), 3.6 (m, 4H), 3.05 (t, 2H), 2.45 (t, 2H), 2.4 (m, 4H), 1.95 (t, 2H), 1.7 (m, 4H), 1.2 (m, 4H), 0.9 (m, 2H)

15 :

MS (+ve ESI) : 560 (M+H)⁺.

Example 34 - Preparation of Compound No. 34 in Table 1

An analogous reaction to that described in example 33, but starting with 5-amino-2-chloropyridine (64.6 mg, 0.50 mmol) yielded the title compound (188.2 mg, 72 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 10.51 (s, 1H), 9.6 (s, 1H), 8.7 (d, 1H), 8.8 (s, 1H), 8.2 (dd, 1H), 7.95 (d, 2H), 7.85 (s, 1H), 7.65 (d, 2H), 7.65 (d, 1H, J = 16Hz), 7.5 (d, 1H), 7.2 (s, 1H), 6.75 (d, 1H, J=16 Hz), 4.2 (t, 2H), 3.99 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.4 (m, 4H), 1.95 (m, 2H) :

25 MS (+ve ESI) : 575 (M+H)⁺.

Example 35 - Preparation of Compound No. 35 in Table 1

An analogous reaction to that described in example 33, but starting with furfurylamine (48.8 mg, 0.50 mmol) yielded the title compound (200 mg, 81 % yield) as a white solid :

-37-

¹H-NMR (DMSO d₆) : 9.55 (s, 1H), 8.45 (m, 2H), 7.9 (d, 2H), 7.85 (s, 1H), 7.6 (m, 3H), 7.45 (d, 1H, J = 16 Hz), 7.2 (s, 1H), 6.6 (d, 1H, J = 16 Hz), 6.4 (m, 1H), 6.25(m, 1H), 4.4 (d, 2H), 4.2 (t, 2H), 3.99 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.4 (m, 4H), 1.95 (m, 2H) :
 MS (+ve ESI) : 544 (M+H)⁺.

5

Example 36 - Preparation of Compound No. 36 in Table 1

An analogous reaction to that described in example 33, but starting with tetrahydrofurfurylamine (50.8 mg, 0.50 mmol) yielded the title compound (61.6 mg, 25 % yield) as a white solid :

¹⁰ ¹H-NMR (DMSO d₆) : 9.6 (s, 1H), 8.5 (s, 1H), 8.05 (t, 1H), 7.9 (d, 2H), 8.85 (s, 1H), 7.59 (d, 2H), 7.4 (d, 1H, J = 16 Hz), 7.2 (s, 1H), 6.6 (d, 1H, J = 16 Hz), 4.2 (t, 2H), 3.99 (s, 3H), 3.9 (m, 1H), 3.8 (m, 1H), 3.6 (m, 1H), 3.59 (m, 4H), 3.25 (m, 2H), 2.45 (t, 2H), 2.4 (m, 4H), 1.95 (m, 2H), 1.8 (m, 2H), 1.6 (m, 2H) :
 MS (+ve ESI) : 548 (M+H)⁺.

15

Example 37 - Preparation of Compound No. 37 in Table 1

An analogous reaction to that described in example 33, but starting with 2-aminopyridine (47.3 mg, 0.50 mmol) yielded the title compound (42.4 mg, 17 % yield) as a white solid :

²⁰ ¹H-NMR (DMSO d₆) : 10.6 (s, 1H), 9.6 (s, 1H), 8.5 (s, 1H), 8.3 (m, 1H), 8.25 (d, 1H), 7.95 (d, 2H), 7.8 (m, 2H), 7.6 (m, 3H), 7.2 (s, 1H), 7.1 (m, 1H), 6.99 (d, 1H, J = 16 Hz), 4.2 (t, 2H), 3.99 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.4 (m, 4H), 1.99 (m, 2H) :
 MS (+ve ESI) : 541 (M+H)⁺.

25

Example 38 - Preparation of Compound No. 38 in Table 1

An analogous reaction to that described in example 33, but starting with 3-aminopyridine (47.3 mg, 0.50 mmol) yielded the title compound (138.9 mg, 57 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 10.35 (s, 1H), 9.6 (s, 1H), 8.85 (m, 1H), 8.5 (s, 1H), 8.25 (d, 1H), 8.15 (dd, 1H), 7.99 (d, 2H), 7.85 (s, 1H), 7.65 (d, 2H), 7.6 (d, 1H, J = 16 Hz), 7.4 (m, 1H), 6.8 (d, 1H, J = 16 Hz), 4.2 (t, 2H), 3.99 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.4 (m, 4H), 1.99 (m, 2H) :

MS (+ve ESI) : 541 (M+H)⁺.

Example 39 - Preparation of Compound No. 39 in Table 1

An analogous reaction to that described in example 33, but starting with 2-aminotoluene (53.9 mg, 0.50 mmol) yielded the title compound (239 mg, 95 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.6 (s, 1H), 9.4 (s, 1H), 8.5 (s, 1H), 8.95 (d, 2H), 8.85 (s, 1H), 7.6 (m, 4H), 7.2 (m, 3H), 7.05 (m, 1H), 6.9 (d, 1H, J = 16 Hz), 4.2 (t, 2H), 3.99 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.4 (m, 4H), 2.25 (s, 3H), 1.99 (m, 2H) :

MS (+ve ESI) : 554 (M+H)⁺.

Example 40 - Preparation of Compound No. 40 in Table 1

An analogous reaction to that described in example 33, but starting with 1,3-dimethylbutylamine (50.9 mg, 0.50 mmol) yielded the title compound (61.8 mg, 25 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.55 (s, 1H), 8.5 (s, 1H), 7.9 (d, 2H), 7.85 (s, 1H), 7.80 (m, 1H), 7.59 (d, 2H), 7.4 (d, 1H, J = 16Hz), 7.2 (s, 1H), 6.5 (d, 1H, J = 16 Hz), 4.2 (t, 2H), 3.99 (s, 3H), 3.99 (m, 1H), 3.6 (m, 4H), 2.45 (t, 2H), 2.4 (m, 4H), 1.95 (m, 2H), 1.6 (m, 1H), 1.4 (m, 1H), 1.2 (m, 1H), 1.05 (d, 3H), 0.85 (d, 6H) :

MS (+ve ESI) : 548 (M+H)⁺.

Example 41 - Preparation of Compound No. 41 in Table 1

An analogous reaction to that described in example 33, but starting with 2,2,2-trifluoroethylamine hydrochloride (67.8 mg, 0.50 mmol) yielded the title compound (7.8 mg, 3 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.59 (s, 1H), 8.65 (t, 1H), 8.5 (s, 1H), 7.9 (d, 2H), 7.85 (s, 1H), 7.6 (d, 2H), 7.5 (d, 1H, J = 16 Hz), 7.2 (s, 1H), 6.6 (d, 1H, J = 16 Hz), 4.2 (t, 2H), 4.05 (m, 2H), 3.99 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.4 (m, 4H), 1.99 (m, 2H) :

MS (+ve ESI) : 546 (M+H)⁺.

Example 42 - Preparation of Compound No. 42 in Table 1

An analogous reaction to that described in example 33, but starting with isobutylamine (36.8 mg, 0.50 mmol) yielded the title compound (39.1 mg, 17 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.52 (s, 1H), 8.5 (s, 1H), 7.95 (m, 1H), 7.9 (d, 2H), 7.85 (s, 1H), 7.58 (d, 2H), 7.38 (d, 1H, J = 16 Hz), 7.2 (s, 1H), 6.6 (d, 1H, J = 16 Hz), 4.18 (t, 2H), 3.97 (s, 3H), 3.58 (m, 4H), 3.0 (t, 2H), 2.48 (t, 2H), 2.35 (m, 4H), 1.95 (m, 2H), 1.75 (m, 1H), 0.89 (d, 6H) : MS (+ve ESI) : 520 (M+H)⁺.

Example 43 - Preparation of Compound No. 43 in Table 1

10 An analogous reaction to that described in example 33, but starting with 2-methylpentylamine (50.9 mg, 0.50 mmol) yielded the title compound (33.5 mg, 13 % yield) as a white solid :

¹H-NMR (300MHz, DMSO d₆) : 9.54 (s, 1H), 8.49 (s, 1H), 7.98 (t, 1H), 7.90 (d, 2H), 7.84 (s, 1H), 7.56 (d, 2H), 7.39 (d, 1H), 7.19 (s, 1H), 6.59 (d, 1H), 4.18 (t, 2H), 3.96 (s, 3H) 3.53-3.61 (m, 4H), 2.93-3.16 (m, 2H), 2.45 (t, 2H), 2.32-2.41 (m, 4H), 1.87-2.02 (m, 2H), 0.95-1.68 (m, 5H), 0.85 (t, 3H), 0.84 (d, 3H) : MS (+ve ESI) : 548 (M+H)⁺.

Example 44 - Preparation of Compound No. 44 in Table 1

20 An analogous reaction to that described in example 3c, but starting with 4-chloro-6-methoxy-7-benzyloxyquinazoline (150 mg, 0.50 mmol) and ethyl 4-aminocinnamate (96 mg, 0.50 mmol), yielded the title compound (226 mg, 92 % yield) as an off-white solid :

¹H-NMR (DMSO d₆) : 11.25 (s, 1H), 8.83 (s, 1H), 8.28 (s, 1H), 7.82-7.80 (m, 4H), 7.66 (d, 1H, J=15.6 Hz), 7.5 (d, 2H), 7.45-7.38 (m, 4H), 6.63 (d, 1H, J=16.2 Hz), 5.34 (s, 2H), 4.21 (q, 2H), 4.02 (s, 3H), 1.26 (t, 3H) : MS (+ve ESI) : 456 (M+H)⁺.

4-Chloro-6-methoxy-7-benzyloxyquinazoline, used as the starting material, was obtained as follows :

- a) A mixture of 2-amino-4-benzyloxy-5-methoxybenzamide (10g, 0.04mol), (prepared according to *J. Med. Chem.* 1977, 20, 146-149), and Gold's reagent (7.4g, 0.05mol) in dioxane (100ml) was stirred and heated at reflux for 24 hours. Sodium acetate (3.02g, 0.037mol) and acetic acid (1.65ml, 0.029mol) were added to the reaction mixture and it was heated for a

further 3 hours. The volatiles were removed by evaporation, water was added to the residue, the solid was collected by filtration, washed with water and dried. Recrystallisation from acetic acid yielded 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (8.7g, 84 % yield) as a white solid.

- 5 b) Dimethylformamide (0.2 ml) was added dropwise to a solution of 6-methoxy-7-benzyloxy-3,4-dihydroquinazolin-4-one (5.00 g, 17.9 mmol) in thionyl chloride (100ml) and the reaction was heated at reflux for 1 hour. The reaction was cooled, excess thionyl chloride was removed *in vacuo* and the residue was azeotroped with toluene (3 x 50 ml) to remove the last of the thionyl chloride. The residue was taken up in dichloromethane (550 ml), the 10 solution was washed with saturated aqueous sodium hydrogen carbonate solution (100 ml) and water (100 ml) and the organic phase was dried over magnesium sulphate. Solvent evaporation *in vacuo* yielded 4-chloro-6,7-dimethoxyquinazoline (4.80 g, 90 % yield) as a pale brown solid :

15 $^1\text{H-NMR}$ (DMSO d_6) : 8.85 (s, 1H), 7.58 (s, 1H), 7.5 (d, 2H), 7.4 (m, 4H), 5.35 (s, 2H), 4.0 (s, 3H) :
 MS (+ve ESI) : 301 ($M+\text{H}^+$).

Example 45 - Preparation of Compound No. 45 in Table 1

An analogous reaction to that described in example 33, but starting with 2-aminoindan 20 (66.9 mg, 0.50 mmol) yielded the title compound (189 mg, 72 % yield) as a white solid :
 $^1\text{H-NMR}$ (300MHz, DMSO d_6) : 9.54 (s, 1H), 8.47 (s, 1H), 8.33 (d, 1H), 7.89 (d, 2H), 7.83 (s, 1H), 7.55 (d, 2H), 7.42 (d, 1H), 7.10-7.27 (m, 5H), 6.55 (d, 1H), 4.51-4.63 (m, 1H), 4.18 (t, 2H), 3.96 (s, 3H), 3.53-3.60 (m, 4H), 3.15-3.25 (m, 2H), 2.75-2.87 (m, 2H), 2.44 (t, 2H), 2.33-2.40 (m, 4H), 1.87-2.01 (m, 2H) ;
 25 MS (+ve ESI) : 580 ($M+\text{H}^+$).

Example 46 - Preparation of Compound No. 46 in Table 1

An analogous reaction to that described in example 33, but starting with 2-thiophene ethylamine (63.9 mg, 0.50 mmol) yielded the title compound (272 mg, 100 % yield) as a white 30 solid :

-41-

- ¹H-NMR (300MHz, DMSO d₆) : 9.55 (s, 1H), 8.48 (s, 1H), 8.18 (t, 1H), 7.90 (d, 2H), 7.84 (s, 1H), 7.57 (d, 2H), 7.41 (d, 1H), 7.30-7.34 (m, 1H), 7.19 (s, 1H), 6.87-6.97 (m, 2H), 6.55 (d, 1H), 4.19 (t, 2H), 3.96 (s, 3H), 3.53-3.62 (m, 4H), 3.38-3.47 (m, 2H), 3.00 (t, 2H), 2.46 (t, 2H), 2.33-2.42 (m, 4H), 1.89-2.01 (m, 2H) ;
- 5 MS (+ve ESI) : 574 (M+H)⁺.

Example 47 - Preparation of Compound No. 47 in Table 1

An analogous reaction to that described in example 33, but starting with 5-methyl-2-(aminomethyl)furan (55.9 mg, 0.50 mmol) yielded the title compound (191 mg, 76 % yield) as
10 a white solid :

- ¹H-NMR (300MHz, DMSO d₆) : 9.54 (s, 1H), 8.48 (s, 1H), 8.43 (t, 1H), 7.90 (d, 2H), 7.84 (s, 1H), 7.56 (d, 2H), 7.43 (d, 1H), 7.20 (s, 1H), 6.59 (d, 1H), 6.13 (d, 1H), 5.98 (d, 1H), 4.33 (d, 2H), 4.19 (t, 2H), 3.97 (s, 3H), 3.52-3.61 (m, 4H), 2.45 (t, 2H), 2.31-2.41 (m, 4H), 2.23 (s, 3H), 1.88-2.02 (m, 2H) ;
- 15 MS (+ve ESI) : 558 (M+H)⁺.

Example 48 - Preparation of Compound No. 48 in Table 1

An analogous reaction to that described in example 33, but starting with 3-aminotetrahydrothiophene-S,S-dioxide dihydrochloride (104.5 mg, 0.50 mmol) yielded the
20 title compound (253 mg, 96 % yield) as a white solid :

- ¹H-NMR (DMSO d₆) : 9.55 (s, 1H), 8.50 (s, 1H), 8.49 (d, 1H), 7.92 (d, 2H), 7.84 (s, 1H), 7.59 (d, 2H), 7.45 (d, 1H), 7.18 (s, 1H), 6.52 (d, 1H), 4.50-4.65 (m, 1H), 4.19 (t, 2H), 3.96 (s, 3H), 3.53-3.61 (m, 4H), 3.40-3.50 (m, 1H), 3.10-3.35 (m, 2H), 2.89-2.98 (m, 1H), 2.32-2.53 (m, 1H), 2.45 (t, 2H), 2.32-2.41 (m, 4H), 2.01-2.18 (m, 1H), 1.88-2.01 (m, 2H) ;
- 25 MS (+ve ESI) : 582 (M+H)⁺.

Example 49 - Preparation of Compound No. 49 in Table 1

An analogous reaction to that described in example 33, but starting with 2-(methylthio)ethylamine (45.8 mg, 0.50 mmol) and yielded the title compound (166.6 mg, 68 %
30 yield) as a white solid :

¹H-NMR (DMSO d₆) : 9.56 (s, 1H), 8.49 (s, 1H), 7.89 (d, 2H, J = 8 Hz), 7.85 (s, 1H), 7.59 (d, 2H, J = 8 Hz), 7.41 (d, 1H, J = 16 Hz), 7.19 (s, 1H), 6.56 (d, 1H, J = 16 Hz), 4.19 (t, 2H, J = 7 Hz), 3.97 (s, 3H), 3.53-3.61 (m, 4H), 3.31-3.40 (m, 2H), 2.59 (t, 2H, J = 7 Hz), 2.45 (t, 2H, J = 7 Hz), 2.32-2.41 (m, 4H), 2.09 (s, 3H), 1.88-2.01 (m, 2H) :

5 MS (+ve ESI) : 538 (M+H)⁺.

Example 50 - Preparation of Compound No. 50 in Table 1

A solution of 1.0N hydrochloric acid in ether (0.50 ml, 0.50 mmol) was added to a solution of ethyl 4-aminocinnamate (96 mg, 0.50 mmol) and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (168 mg, 0.50 mmol), in isopropanol (5.0 ml). The reaction was heated at 40 °C for 30 minutes and then at 83 °C for 12 hours. The reaction was allowed to cool to ambient temperature and the solid which had precipitated was collected by suction filtration and washed with diethyl ether (2 x 10 ml). Drying of this material yielded the title compound (248 mg, 94 % yield) as a white solid :

15 ¹H-NMR (DMSO d₆) : 11.55 (s, 1H), 11.10 (s, 1H), 8.88 (s, 1H), 8.50 (s, 1H) 7.85 (m, 4H), 7.68 (d, 1H, J = 16 Hz), 7.45 (s, 1H), 6.63 (d, 1H, J = 16 Hz), 4.30 (t, 2H), 4.20 (q, 2H), 4.05 (s, 3H), 3.98 (m, 2H), 3.82 (m, 2H), 3.45 (m, 2H), 3.30 (m, 2H), 3.10 (m, 2H), 2.35 (m, 2H), 1.25 (t, 3H) ;

MS (+ve ESI) : 493 (M+H)⁺.

20

Biological Data

The compounds of the invention inhibit the serine/threonine kinase activity of the aurora2 kinase and thus inhibit the cell cycle and cell proliferation. These properties may be assessed, for example, using one or more of the procedures set out below:

25

(a) In Vitro aurora2 kinase inhibition test

This assay determines the ability of a test compound to inhibit serine/threonine kinase activity. DNA encoding aurora2 may be obtained by total gene synthesis or by cloning. This 30 DNA may then be expressed in a suitable expression system to obtain polypeptide with serine/threonine kinase activity. In the case of aurora2, the coding sequence was isolated from

cDNA by polymerase chain reaction (PCR) and cloned into the BamH1 and Not1 restriction endonuclease sites of the baculovirus expression vector pFastBac HTc (GibcoBRL/Life technologies). The 5' PCR primer contained a recognition sequence for the restriction endonuclease BamH1 5' to the aurora2 coding sequence. This allowed the insertion of the aurora2 gene in frame with the 6 histidine residues, spacer region and rTEV protease cleavage site encoded by the pFastBac HTc vector. The 3' PCR primer replaced the aurora2 stop codon with additional coding sequence followed by a stop codon and a recognition sequence for the restriction endonuclease Not1 . This additional coding sequence (5' TAC CCA TAC GAT GTT CCA GAT TAC GCT TCT TAA 3') encoded for the polypeptide sequence

5 YPYDVPDYAS. This sequence, derived from the influenza hemagglutin protein, is frequently used as a tag epitope sequence that can be identified using specific monoclonal antibodies. The recombinant pFastBac vector therefore encoded for an N-terminally 6 his tagged, C terminally influenza hemagglutin epitope tagged aurora2 protein. Details of the methods for the assembly of recombinant DNA molecules can be found in standard texts, for

10 example Sambrook et al. 1989, Molecular Cloning - A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press and Ausubel et al. 1999, Current Protocols in Molecular Biology, John Wiley and Sons Inc.

Production of recombinant virus can be performed following manufacturer's protocol from GibcoBRL. Briefly, the pFastBac-1 vector carrying the aurora2 gene was transformed into E. coli DH10Bac cells containing the baculovirus genome (bacmid DNA) and via a transposition event in the cells, a region of the pFastBac vector containing gentamycin resistance gene and the aurora2 gene including the baculovirus polyhedrin promoter was transposed directly into the bacmid DNA. By selection on gentamycin, kanamycin, tetracycline and X-gal, resultant white colonies should contain recombinant bacmid DNA encoding aurora2. Bacmid DNA was

15 extracted from a small scale culture of several BH10Bac white colonies and transfected into Spodoptera frugiperda Sf21 cells grown in TC100 medium (GibcoBRL) containing 10% serum using CellFECTIN reagent (GibcoBRL) following manufacturer's instructions. Virus particles were harvested by collecting cell culture medium 72 hrs post transfection. 0.5 mls of medium was used to infect 100 ml suspension culture of Sf21s containing 1×10^7 cells/ml.

20 Cell culture medium was harvested 48 hrs post infection and virus titre determined using a

standard plaque assay procedure. Virus stocks were used to infect Sf9 and "High 5" cells at a multiplicity of infection (MOI) of 3 to ascertain expression of recombinant aurora2 protein.

For the large scale expression of aurora2 kinase activity, Sf21 insect cells were grown at 28°C in TC100 medium supplemented with 10% foetal calf serum (Viralex) and 0.2% F68

5 Pluronic (Sigma) on a Wheaton roller rig at 3 r.p.m. When the cell density reached 1.2×10^6 cells ml⁻¹ they were infected with plaque-pure aurora2 recombinant virus at a multiplicity of infection of 1 and harvested 48 hours later. All subsequent purification steps were performed at 4°C. Frozen insect cell pellets containing a total of 2.0×10^8 cells were thawed and diluted with lysis buffer (25 mM HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid]) pH7.4 at 4°C , 100 mM KCl, 25 mM NaF, 1 mM Na₃VO₄, 1 mM PMSF (phenylmethylsulphonyl fluoride), 2 mM 2-mercaptoethanol, 2 mM imidazole, 1 µg/ml aprotinin, 1 µg/ml pepstatin, 1 µg/ml leupeptin), using 1.0 ml per 3×10^7 cells. Lysis was achieved using a dounce homogeniser, following which the lysate was centrifuged at 41,000g for 35 minutes. Aspirated supernatant was pumped onto a 5 mm diameter chromatography column containing 500 µl Ni NTA (nitrilo-tri-acetic acid) agarose (Qiagen, product no. 10 30250) which had been equilibrated in lysis buffer. A baseline level of UV absorbance for the eluent was reached after washing the column with 12 ml of lysis buffer followed by 7 ml of wash buffer (25 mM HEPES pH7.4 at 4°C , 100 mM KCl, 20 mM imidazole, 2 mM 2-mercaptopethanol). Bound aurora2 protein was eluted from the column using elution buffer (25 mM HEPES pH7.4 at 4°C , 100 mM KCl, 400 mM imidazole, 2 mM 2-mercaptopethanol). An elution fraction (2.5 ml) corresponding to the peak in UV absorbance was collected. The elution fraction, containing active aurora2 kinase, was dialysed exhaustively against dialysis buffer (25 mM HEPES pH7.4 at 4°C , 45% glycerol (v/v), 100 mM KCl, 0.25% Nonidet P40 (v/v), 1 mM dithiothreitol).

20 25 Each new batch of aurora2 enzyme was titrated in the assay by dilution with enzyme diluent (25mM Tris-HCl pH7.5, 12.5mM KCl, 0.6mM DTT). For a typical batch, stock enzyme is diluted 1 in 666 with enzyme diluent & 20µl of dilute enzyme is used for each assay well. Test compounds (at 10mM in dimethylsulphoxide (DMSO)) were diluted with water & 10µl of diluted compound was transferred to wells in the assay plates. "Total" & 30 "blank" control wells contained 2.5% DMSO instead of compound. Twenty microlitres of freshly diluted enzyme was added to all wells, apart from "blank" wells. Twenty microlitres

of enzyme diluent was added to "blank" wells. Twenty microlitres of reaction mix (25mM Tris-HCl, 78.4mM KCl, 2.5mM NaF, 0.6mM dithiothreitol, 6.25mM MnCl₂, 6.25mM ATP, 7.5μM peptide substrate [biotin-LRRWSLGLRRWSLGLRRWSLGLRRWSLG]) containing 0.2μCi [γ^{33} P]ATP (Amersham Pharmacia, specific activity ≥2500Ci/mmol) was then added to 5 all test wells to start the reaction. The plates were incubated at room temperature for 60 minutes. To stop the reaction 100μl 20% v/v orthophosphoric acid was added to all wells. The peptide substrate was captured on positively-charged nitrocellulose P30 filtermat (Whatman) using a 96-well plate harvester (TomTek) & then assayed for incorporation of 33 P with a Beta plate counter. "Blank" (no enzyme) and "total" (no compound) control values were used to 10 determine the dilution range of test compound which gave 50% inhibition of enzyme activity.

In this test, compound 18 in Table 1 gave 50% inhibition of enzyme activity at a concentration of 0.117μM.

(b) In Vitro cell proliferation assay

15 This assay determines the ability of a test compound to inhibit the growth of adherent mammalian cell lines, for example the human tumour cell line MCF7.

MCF-7 (ATCC HTB-22) or other adherent cells were typically seeded at 1 x 10³ cells per well (excluding the peripheral wells) in DMEM (Sigma Aldrich) without phenol red, plus 10% foetal calf serum, 1% L-glutamine and 1% penicillin/streptomycin in 96 well tissue 20 culture treated clear plates (Costar). The following day (day 1), the media was removed from a no treatment control plate and the plate stored at -80°C. The remaining plates were dosed with compound (diluted from 10mM stock in DMSO using DMEM (without phenol red, 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin). Untreated control wells were included on each plate. After 3 days in the presence / absence of compound (day 4) the media was 25 removed and the plates stored at -80°C. Twenty four hours later the plates were thawed at room temperature and cell density determined using the CyQUANT cell proliferation assay kit (c-7026/c-7027 Molecular Probes Inc.) according to manufacturers directions. Briefly, 200μl of a cell lysis / dye mixture (10μl of 20X cell lysis buffer B, 190μl of sterile water, 0.25μl of CYQUANT GR dye) was added to each well and the plates incubated at room 30 temperature for 5 minutes in the dark. The fluorescence of the wells was then measured using a fluorescence microplate reader (gain 70, 2 reads per well, 1 cycle with excitation 485nm and

emission 530nm using a CytoFluor plate reader (PerSeptive Biosystems Inc.)). The values from day 1 and day 4 (compound treated) together with the values from the untreated cells were used to determine the dilution range of a test compound that gave 50% inhibition of cell proliferation. Compound 18 in Table 1 was effective in this test at 6.38 μ M.

5 These values could also be used to calculate the dilution range of a test compound at which the cell density dropped below the day 1 control value. This indicates the cytotoxicity of the compound.

10 (c) In Vitro cell cycle analysis assay

This assay determines the ability of a test compound to arrest cells in specific phases of the cell cycle. Many different mammalian cell lines could be used in this assay and MCF7 cells are included here as an example. MCF-7 cells were seeded at 3×10^5 cells per T25 flask (Costar) in 5 ml DMEM (no phenol red 10% FCS, 1% L-glutamine 1% penicillin / streptomycin). Flasks were then incubated overnight in a humidified 37°C incubator with 5% CO₂. The following day 1ml of DMEM (no phenol red 10% FCS, 1% L-glutamine 1% penicillin / streptomycin) carrying the appropriate concentration of test compound solubilised in DMSO was added to the flask. A no compound control treatments was also included (0.5% DMSO). The cells were then incubated for a defined time (usually 24 hours) with compound.

20 After this time the media was aspirated from the cells and they were washed with 5ml of prewarmed (37°C) sterile PBSA, then detached from the flask by brief incubation with trypsin and followed by resuspension in 10ml of 1% Bovine Serum Albumin (BSA, Sigma-Aldrich Co.) in sterile PBSA. The samples were then centrifuged at 2200rpm for 10 min. The supernatant was aspirated and the cell pellet was resuspended in 200 μ l of 0.1% (w/v) Tris sodium citrate, 0.0564% (w/v) NaCl, 0.03% (v/v) Nonidet NP40, [pH 7.6]. Propidium Iodide (Sigma Aldrich Co.) was added to 40 μ g/ml and RNAase A (Sigma Aldrich Co.) to 100 μ g/ml. The cells were then incubated at 37°C for 30 minutes. The samples were centrifuged at 2200rpm for 10 min, the supernatant removed and the remaining pellet (nuclei) resuspended in 200 μ l of sterile PBSA. Each sample was then syringed 10 times using 21 gauge needle.

25 The samples were then transferred to LPS tubes and DNA content per cell analysed by Fluorescence activated cell sorting (FACS) using a FACScan flow cytometer (Becton

Dickinson). Typically 25000 events were counted and recorded using CellQuest v1.1 software (Verity Software). Cell cycle distribution of the population was calculated using Modfit software (Verity Software) and expressed as percentage of cells in G0/G1, S and G2/M phases of the cell cycle.

- 5 Treating MCF7 cells with 12.76 μ M Compound 18 in Table 1 for 24 hours produced the following changes in cell cycle distribution:

Treatment	% Cells in G1	% Cells in S	% Cells in G2/M
DMSO (control)	65.58	22	9.81
12.76 μ M Compound 18	30.96	19.42	49.62

PCT | 4B 00 | 0 62

TC

18-9-00

dstra Genera PLC

THIS PAGE BLANK (USPTO)